Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2211-2220 of 11704

Edit search filters
  1. A Study To Evaluate Mesenchymal Stem Cells To Treat Multiple System Atrophy

    Rochester, MN

  2. A Study Of Intranasal Esketamine For Rapid Reduction Of The Symptoms Of MDD

    Rochester, MN

  3. A Study To Assess The Efficacy And Safety Of Efgartigimod IV In Adult Participants With Primary Immune Thrombocytopenia

    Scottsdale/Phoenix, AZ

  4. Study Of Targeted Therapies For The Treatment Of Adult Participants With Moderate To Severe Crohn's Disease

    Rochester, MN

  5. Impact of Ureteral Stent and Sheaths Size on Post-Operative Pain

    Rochester, MN

  6. A Phase 2 Study Of The Safety And Efficacy Of Brepocitinib In Adults With Cutaneous Sarcoidosis (BEACON)

    Scottsdale/Phoenix, AZ

  7. Acoramidis Transthyretin Amyloidosis Prevention Trial In The Young (ACT-EARLY) Study In Asymptomatic Carriers Of A Pathogenic TTR Variant

    Rochester, MN

  8. Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence after Liver Transplantation

    Scottsdale/Phoenix, AZ

  9. A Study To Assess The Safety, Tolerability, And Pharmacokinetics Of ABSK-011 In Patients With Advanced Solid Tumor

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer